Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • The use of darunavir/ritonavir monotherapy for maintenance of viral suppression has been evaluated in several trials
    • In the PIVOT trial, boosted PI monotherapy (majority of patients received darunavir/ritonavir) was noninferior to continuing triple-drug antiretroviral therapy for the primary endpoint of loss of future drug options[Paton 2015]
    • The MONET trial found that noninferiority of darunavir/ritonavir monotherapy to darunavir/ritonavir monotherapy plus NRTIs was not maintained for 144 weeks of therapy[Arribas 2012]

Action required

Keywords: Switch Strategies

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.